Payment overview · 2025
General Payments
$224.00
10 reported records · 5 companies
Healthcare provider profile · identity verified
Shahida Haq Khan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YPSILANTI, MI · NPI 1740267921
Verified facts
What the public records show
CMS Open Payments records show Shahida Haq Khan, M.D. received $224.00 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $116.40 | 52.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.53 | 21.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.47 | 9.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.06 | 9.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.54 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.00 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $116.40 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 229 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 384 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 99 |
| Gabapentin | Gabapentin | 353 | 56 |
| Lisinopril | Lisinopril | 245 | 55 |
| Omeprazole | Omeprazole | 239 | 56 |
| Eliquis | Apixaban | 229 | 30 |
| Metformin Hcl | Metformin Hcl | 208 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 47 |
| Losartan Potassium | Losartan Potassium | 145 | 35 |
| Ibuprofen | Ibuprofen | 142 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 43 |
| Furosemide | Furosemide | 119 | 32 |
| Trazodone Hcl | Trazodone Hcl | 114 | 24 |
| Lorazepam | Lorazepam | 109 | 13 |
| Simvastatin | Simvastatin | 103 | 25 |
| Alprazolam | Alprazolam | 102 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 22 |
| Azithromycin | Azithromycin | 96 | 62 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 90 | 11 |
| Bumetanide | Bumetanide | 87 | 12 |
| Prednisone | Prednisone | 78 | 31 |
| Tramadol Hcl | Tramadol Hcl | 77 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 25 |
| Glipizide | Glipizide | 74 | 14 |
| Methadone Hcl | Methadone Hcl | 74 | suppressed |
| Ozempic | Semaglutide | 74 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 72 | 19 |
| Carvedilol | Carvedilol | 68 | 21 |
| Spironolactone | Spironolactone | 68 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Amoxicillin | Amoxicillin | 56 | 36 |
| Allopurinol | Allopurinol | 54 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 11 |
| Baclofen | Baclofen | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 13 |
| Diazepam | Diazepam | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 13 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Mirtazapine | Mirtazapine | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 12 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 38 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Famotidine | Famotidine | 37 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Meloxicam | Meloxicam | 36 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Progesterone | Progesterone, Micronized | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 12 | suppressed |
| Soaanz | Torsemide | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.00 · 10 records | Exact Sciences Corporation | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, PREVNAR 20, Wegovy, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error